Lactylation in cardiovascular diseases (CVDs) The involvement of lactylation in the pathogenesis of CVDs, particularly atherosclerosis and myocardial infarction, as well as in conditions such as vascular calcification, neointimal hyperplasia, pulmonary hypertension, heart failure, and radiation-induced heart damage (RIHD), is becoming increasingly elucidated
doi:10.1007/s10522-025-10315-x PMC:PMC12411320 (note: a correction was published 15 November 2025, doi:10.1007/s10522-025-10326-8, replacing Figs
Our medical team will design a tailored protocol to support fat metabolism, body composition, and long-term metabolic health through safe, science-backed care.
After scrapping a Biden-era plan to cover obesity drugs in early 2025, the Trump administration reversed course: it struck deals with Novo Nordisk and Eli Lilly in November 2025 to cut GLP-1 prices, and a voluntary Medicare demonstration begins July 1, 2026 that lets participating drug plans cover GLP-1s for weight loss with a $50 monthly copay